PE20061390A1 - Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas - Google Patents

Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas

Info

Publication number
PE20061390A1
PE20061390A1 PE2006000515A PE2006000515A PE20061390A1 PE 20061390 A1 PE20061390 A1 PE 20061390A1 PE 2006000515 A PE2006000515 A PE 2006000515A PE 2006000515 A PE2006000515 A PE 2006000515A PE 20061390 A1 PE20061390 A1 PE 20061390A1
Authority
PE
Peru
Prior art keywords
same
hydroxamic acid
procedures
production
suberoylanilide hydroxamic
Prior art date
Application number
PE2006000515A
Other languages
English (en)
Spanish (es)
Inventor
Wong Jeannie Chow
Erik A Dienemann
Craig Ikeda
Pavol Rajniak
Cindy Starbuck
Quinxi Wang
Vincent R Capodanno
Thomas A Miller
Brian Sell
Benjamin Max Cohen
Hsien-Hsin Tung
Robert A Reed
Justin Moser
Kimberly Gallagher
Aaron S Cote
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20061390A1 publication Critical patent/PE20061390A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2006000515A 2005-05-20 2006-05-16 Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas PE20061390A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
PE20061390A1 true PE20061390A1 (es) 2007-01-15

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000515A PE20061390A1 (es) 2005-05-20 2006-05-16 Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas

Country Status (20)

Country Link
US (4) US8093295B2 (enExample)
EP (2) EP1853245A2 (enExample)
JP (2) JP5264174B2 (enExample)
KR (2) KR100884500B1 (enExample)
AR (1) AR055953A1 (enExample)
AU (3) AU2006249440C1 (enExample)
BR (1) BRPI0605893A (enExample)
CA (1) CA2580367C (enExample)
CR (1) CR8912A (enExample)
DO (1) DOP2006000113A (enExample)
EC (1) ECSP077263A (enExample)
IL (1) IL181070A0 (enExample)
MA (1) MA28804B1 (enExample)
MX (1) MX2007002047A (enExample)
MY (1) MY144613A (enExample)
NI (1) NI200700031A (enExample)
NZ (2) NZ553204A (enExample)
PE (1) PE20061390A1 (enExample)
TW (2) TWI365068B (enExample)
WO (2) WO2006127321A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2010043904A2 (en) 2008-10-15 2010-04-22 Generics [Uk] Limited Improved process
WO2010061219A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Polymorphs
CA2744458A1 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
WO2018011811A2 (en) * 2016-07-13 2018-01-18 Rappaport Family Institute For Research In The Medical Sciences Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
WO2000021979A2 (en) 1998-10-13 2000-04-20 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide and their use as histone deacetylase inhibitor
KR20020007398A (ko) 1999-05-03 2002-01-26 추후제출 히스톤 탈아세틸화효소의 억제
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
BR0014254A (pt) * 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
KR20100035666A (ko) 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002102323A2 (en) * 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Novel human histone deacetylases
EP1443928B1 (en) * 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
JP2006508986A (ja) * 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
AU2004228011A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
HRP20060080A2 (en) * 2003-08-26 2006-07-31 Sloan-Kettering Institute For Cancer Research Method of treating cancer with hdac inhibitors
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2007022408A2 (en) 2005-08-18 2007-02-22 Merck & Co., Inc. Combination methods of saha and targretin for treating cancer
CA2622136A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
JP2009514879A (ja) 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer

Also Published As

Publication number Publication date
IL181070A0 (en) 2007-07-04
KR20070062505A (ko) 2007-06-15
US8093295B2 (en) 2012-01-10
AU2006249440B2 (en) 2009-03-12
CA2580367A1 (en) 2006-11-30
EP1853245A2 (en) 2007-11-14
KR100993135B1 (ko) 2010-11-10
TW201034660A (en) 2010-10-01
CA2580367C (en) 2012-08-21
TW200727892A (en) 2007-08-01
AR055953A1 (es) 2007-09-12
US8450372B2 (en) 2013-05-28
KR100884500B1 (ko) 2009-02-20
JP5264174B2 (ja) 2013-08-14
JP2008519081A (ja) 2008-06-05
MX2007002047A (es) 2007-04-12
DOP2006000113A (es) 2006-10-31
KR20080113135A (ko) 2008-12-26
NZ594669A (en) 2013-02-22
NZ553204A (en) 2011-09-30
JP2011251985A (ja) 2011-12-15
WO2006127319A3 (en) 2007-03-29
CR8912A (es) 2008-02-21
US20100119596A1 (en) 2010-05-13
WO2006127319A2 (en) 2006-11-30
AU2009201652B2 (en) 2011-10-06
ECSP077263A (enExample) 2007-04-26
AU2010201359A1 (en) 2010-04-29
NI200700031A (es) 2008-03-03
US8288440B2 (en) 2012-10-16
WO2006127321A2 (en) 2006-11-30
US20100113829A1 (en) 2010-05-06
EP2292221A2 (en) 2011-03-09
AU2009201650B2 (en) 2011-09-15
WO2006127321A3 (en) 2007-03-22
AU2009201650A1 (en) 2009-05-21
JP5308486B2 (ja) 2013-10-09
TWI365068B (en) 2012-06-01
AU2006249440C1 (en) 2009-08-13
TWI415603B (zh) 2013-11-21
US20100112046A1 (en) 2010-05-06
EP2292221A3 (en) 2011-08-10
AU2009201652A1 (en) 2009-05-21
MY144613A (en) 2011-10-04
BRPI0605893A (pt) 2007-12-18
MA28804B1 (fr) 2007-08-01
AU2006249440A1 (en) 2006-11-30
US20080132575A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
DOP2006000170A (es) Nuevos derivados de espirocromanona
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA201171399A1 (ru) Способ и композиция для улучшения всасывания лекарственных средств
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NZ602510A (en) Treatment of lupus nephritis using laquinimod
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
ATE530524T1 (de) Substituierte sulfonamid-derivate
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
BR112012015433A2 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
CY1110563T1 (el) Παραγωγο του ισοξαζολικου οξεος για την ανακουφιση νευροπαθητικου πονου

Legal Events

Date Code Title Description
FC Refusal